Close Menu

NEW YORK — Women's health diagnostic firm Progenity announced after the close of the market on Monday a 38 percent year-over-year increase in third quarter revenues as test volumes ticked up 12 percent.

For the three-month period ended Sept. 30, Progenity reported $25.9 million in revenue, up from $18.8 million in the year-ago quarter but short of the consensus Wall Street estimate of $34.7 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Bloomberg reports AstraZeneca may conduct another study of its candidate SARS-CoV-2 vaccine after dosing error.

Moderna is applying for an Emergency Use Authorization for its coronavirus vaccine, according to the New York Times.

The National Health Service is to conduct a trial of Grail's blood-based screening test for cancer.

In PLOS this week: somatic mutation patterns of glioblastomas among Lebanese patients, phenome-wide study using UK Biobank data, and more.